📊 poll results
Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?
🏆 Leading: It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.

It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight. is leading so far with 100%.

Everyone who has answered so far is voting from China.

The poll is still live and picked up a vote today.

hewsay who say wut? 💬
📊 poll results
Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?
100%
Leading answer
It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.
results so far
hewsay.com ↗

Discussion

Vote on one of these nextModerna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?A 1964 Shelby Cobra Daytona Coupe Just Sold for $42.9 Million, Smashing the American Car Record — Historic Bargain or Sign of a Wildly Overheated Market?The $13.9 Million F.P. Journe Résonance: Proof Independent Watchmaking Has Conquered Horology, or a Speculative Bubble in the Making?
react to this tea 👀
It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.
It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype.
It's an overreaction -- a short-squeeze, not a rational re-rating. Even after nearly tripling, Moderna's stock remains roughly 67% below its August 2021 peak, and its core COVID vaccine business had been shrinking for years -- one successful trial doesn't erase that structural decline overnight. Trading volume spiked to about 1,819% above average and short sellers reportedly lost $5.5 billion in the move, hallmarks of a technically-driven squeeze where forced short covering, not careful valuation, drove the size and speed of the spike.